Glutamic Acid

Glutamic Acid

SCHEMBL2501322

C[C@@H](O)[C@H](N)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.69
GRM8 O00222 2/20 0.69
GRM6 O15303 2/20 0.69
GRM7 Q14831 2/20 0.69
GRM4 Q14833 2/20 0.69
GRIN2D O15399 1/20 0.69
GRIN3B O60391 1/20 0.69
GSR P00390 1/20 0.69
GRIK1 P39086 1/20 0.69
GRM5 P41594 1/20 0.69
GRIA1 P42261 1/20 0.69
GRIA2 P42262 1/20 0.69
GRIA3 P42263 1/20 0.69
SLC1A3 P43003 1/20 0.69
SLC1A2 P43004 1/20 0.69
SLC1A1 P43005 1/20 0.69
GRIA4 P48058 1/20 0.69
GRIN1 Q05586 1/20 0.69
GRIN2A Q12879 1/20 0.69
GRIK2 Q13002 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL1767317 1.00 CYP1A2 (0.69) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL1527702 1.00 CYP1A2 (0.69) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL25337565 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27287949 0.93 CYP1A2 (0.60) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27691480 0.93 CYP1A2 (0.60) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL6130151 0.92 SLC1A3 (0.58) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL9716073 0.90 CYP1A2 (0.56) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL9716085 0.90 CYP1A2 (0.56) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL23777456 0.87 SLC1A3 (0.53) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27591999 0.87 CYP1A2 (0.53) CYP1A2GRM8GRM6GRM7GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102307584-A YL-based insulin-like growth factors exhibiting high activity at the insulin receptor UNIV INDIANA RES & TECH CORP 2012-01-04 CN disclosed
US-20110245164-A1 YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245164-A1 YL-BASED INSULIN-LIKE GROWTH FACTORS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR IGF1R, INSR, IGFBP1 CYP1A2 3365/4885GRM8 1739/4885GRM6 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.